Evox Therapeutics plc (NASDAQ:EVOXW) Sees Large Drop in Short Interest

Evox Therapeutics plc (NASDAQ:EVOXW) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 10,272 shares, a decline of 87.3% from the April 15th total of 80,904 shares. Based on an average daily trading volume, of 3,013 shares, the short-interest ratio is presently 3.4 days.

Evox Therapeutics Trading Down 2.7%

Shares of NASDAQ:EVOXW traded down $0.01 on Wednesday, hitting $0.36. 2,500 shares of the company were exchanged, compared to its average volume of 44,108. Evox Therapeutics has a 1-year low of $0.30 and a 1-year high of $0.62. The stock has a 50 day moving average price of $0.40.

Evox Therapeutics plc is a biotechnology company developing therapeutics built on engineered extracellular vesicles (EVs), commonly referred to as exosomes, designed to deliver a broad range of therapeutic payloads. The company’s platform focuses on using naturally occurring nanoscale vesicles as vehicles to carry biologics—such as RNA, proteins and other macromolecules—into target cells and tissues. Evox aims to leverage the innate properties of EVs for targeted delivery, biodistribution and reduced immunogenicity compared with some synthetic delivery systems.

The company’s research and development activities center on engineering EVs for tissue-specific targeting and intracellular delivery, with the goal of addressing diseases that are difficult to treat with conventional approaches, including disorders of the central nervous system and certain rare genetic conditions.